About Queuine/queuosine transporter SLC35F2
Queuine/queuosine transporter SLC35F2 (SLC35F2) is a protein
from Homo sapiens identified by UniProt accession
Q8IXU6, 374 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | Queuine/queuosine transporter SLC35F2 |
|---|
| UniProt accession | Q8IXU6 |
|---|
| Gene | SLC35F2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 374 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (37)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.34
- white matter microstructure measurement · score 0.32
- leukocyte count · score 0.28
- breast cancer · score 0.09
- papillary thyroid carcinoma · score 0.08
- lung adenocarcinoma · score 0.08
- cancer · score 0.06
- neoplasm · score 0.05
- pulse pressure measurement · score 0.03
- non-small cell lung carcinoma · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IXU6-F1 | alphafold | PREDICTED | 82.43 | — |
Amino-acid sequence (374 residues)
MEADSPAGPG APEPLAEGAA AEFSSLLRRI KGKLFTWNIL KTIALGQMLS LCICGTAITS QYLAERYKVN TPMLQSFINY CLLFLIYTVM LAFRSGSDNL LVILKRKWWK YILLGLADVE ANYVIVRAYQ YTTLTSVQLL DCFGIPVLMA LSWFILHARY RVIHFIAVAV CLLGVGTMVG ADILAGREDN SGSDVLIGDI LVLLGASLYA ISNVCEEYIV KKLSRQEFLG MVGLFGTIIS GIQLLIVEYK DIASIHWDWK IALLFVAFAL CMFCLYSFMP LVIKVTSATS VNLGILTADL YSLFVGLFLF GYKFSGLYIL SFTVIMVGFI LYCSTPTRTA EPAESSVPPV TSIGIDNLGL KLEENLQETH SAVL
Explore Queuine/queuosine transporter SLC35F2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets